Form 4: Boundless Bio Executive Reprices Stock Options

Jessica Oien, Chief Legal Officer and Corporate Secretary of Boundless Bio, Inc., repriced several stock option grants on August 19, 2024.

Summary

• On August 19, 2024, Jessica Oien, Chief Legal Officer and Corporate Secretary of Boundless Bio, Inc., engaged in transactions involving stock options.
• Oien repriced multiple stock option grants, initially priced between $4.10 and $16.00, to a new exercise price of $3.56 per share.
• The repriced options vest over various periods, with some starting as early as August 30, 2022, and others beginning in 2023 and 2024.
• A total of 191,661 options were repriced.
• The original exercise price will be reinstated if the options are exercised or the reporting person's employment is terminated for any reason other than a 'qualifying termination' before August 19, 2026, a change in control, or a qualifying termination.

Sentiment

Score: 6

Explanation: The document itself is neutral as it is a regulatory filing. The repricing could be seen as slightly positive as it incentivizes the executive, but also potentially concerning if the original options were significantly out-of-the-money.

Positives

• The repricing of stock options at fair market value could incentivize the executive to remain with the company.
• The vesting schedules provide a long-term incentive for the executive.

Risks

• The original exercise price of the options will be reinstated if the reporting person's employment is terminated for any reason other than a 'qualifying termination' before August 19, 2026, a change in control, or a qualifying termination, which could disincentivize the executive if termination is being considered.
• The definition of 'qualifying termination' is limited to involuntary termination due to reduction in force or termination due to death or disability, which may not cover all circumstances.

Industry Context

Stock option repricing is a common practice to incentivize employees, especially in volatile market conditions or when a company's stock price has declined. It ensures that options remain a valuable part of the compensation package.

Comparison to Industry Standards

• Stock option repricing is a relatively common practice, especially among growth-stage biotech companies like Boundless Bio.
• Many companies in the biotech sector use stock options as a key component of executive compensation to align management's interests with those of shareholders.
• Repricing can be compared to actions taken by companies like Global Blood Therapeutics (acquired by Pfizer) or Sarepta Therapeutics, which have adjusted option terms to retain key personnel.

Stakeholder Impact

• Shareholders may view the repricing as a positive move to retain key personnel.
• Employees holding stock options may be affected by the repricing, depending on their individual option terms.

Key Dates